论文部分内容阅读
此项研究旨在评价肿瘤特异性细胞毒T淋巴细胞(CTL)和LAK细胞治疗Ⅳ期原发性肝癌的疗效。 将26例Ⅳ期肝痛患者分为2组,LAK细胞治疗组(8例)和肿瘤特异性CTL治疗组(18例)。体外扩增的效应细胞均通过肝动脉回输给患者。LAK细胞输入细胞数为1.9×10~9～14.4×10~9,IL-2为1×10~6U,CTL输入细胞数为0.4×10~9～5.3×10~9,IL-2为0～28×10~6U,治疗期间患者未接受其它治疗。 应用超声显像和CT检查肿瘤大小,两组患者的生存率用Kaplan-Meier法进行评价。LAK细胞治疗组8例中有效4例,但均为轻度消退(肿瘤体积减少<50％),其中3例在治疗结束后8个月内死亡,仅1例在治疗后存活27个月。CTL治疗组18例中3例为完全
This study aimed to evaluate the efficacy of tumor-specific cytotoxic T lymphocytes (CTL) and LAK cells in the treatment of stage IV primary liver cancer. Twenty-six patients with stage IV liver pain were divided into two groups: LAK cell therapy group (8 cases) and tumor-specific CTL treatment group (18 cases). In vitro amplified effector cells were transfused to the patient via the hepatic artery. LAK cell input cell number was 1.9×10~9~14.4×10~9, IL-2 was 1×10~6U, CTL input cell number was 0.4×10~9~5.3×10~9, IL-2 was 0. ~ 28 × 10 ~ 6U, patients did not receive other treatment during treatment. The tumor size was examined by ultrasound imaging and CT. The survival rate of the two groups was evaluated by Kaplan-Meier method. In the LAK cell therapy group, 4 cases were effective in 8 cases, but all were mildly subsided (tumor volume reduction <50%), of which 3 cases died within 8 months after the end of treatment, and only 1 case survived for 27 months after treatment. Three out of 18 cases in the CTL treatment group were complete